YDES

YD Bio Ltd

Sep 22 • 02:42PM ET

18.70

-1.08 -5.46 %

Healthcare • Biotechnology • Taiwan • NASD

Index	-	P/E	-	EPS (ttm)	-0.99	Insider Own	76.18%	Shs Outstand	3.36M	Perf Week	9.36%
Market Cap	61.98M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.79M	Perf Month	96.84%
Enterprise Value	61.97M	PEG	-	EPS next Q	-	Inst Own	16.13%	Short Float	0.43%	Perf Quarter	59.15%
Income	-2.97M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.05	Perf Half Y	63.60%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-43.61%	Short Interest	0.00M	Perf YTD	66.22%
Book/sh	-4.77	P/C	6198.04	EPS next 5Y	-	ROE	-	52W High	31.00 -39.68%	Perf Year	62.50%
Cash/sh	0.00	P/FCF	-	EPS past 3/5Y	- -33.79%	ROIC	-	52W Low	5.30 252.83%	Perf 3Y	83.15%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	18.73% 31.23%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	14.61%	Oper. Margin	-	ATR (14)	2.86	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.02	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	56.23	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.02	EPS Q/Q	-116.03%	SMA20	17.28%	Beta	-	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	39.08%	Rel Volume	0.40	Prev Close	19.78
Employees	4	LT Debt/Eq	-	Earnings	-	SMA200	57.65%	Avg Volume	69.12K	Price	18.70
IPO	Dec 23, 2020	Option/Short	No / No	EPS/Sales Surpr.	- -	Trades		Volume	22,160	Change	-5.46%

Aug-29-25 07:30AM

YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market

(PR Newswire) +135.85%

YD Bio Ltd. engages in the development of detection and therapeutic technologies. It offers cancer detection products, regenerative ophthalmology products, and exosome science. The company was founded on February 6, 2024 and is headquartered in Taipei, Taiwan.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

YDES

YD Bio Ltd

Upgrade your FINVIZ experience